NewLimit
Backed by
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Data Scientist
Computational Biologist
Director, Operations
Senior/Research Associate
Scientist/Senior Scientist, Immunology
Scientist/Senior Scientist
Senior Research Associate, Metabolism
Senior/Research Associate, Drug Product Development
Senior/Research Associate, Functional Genomics
Senior Research Associate, Single Cell Technology
Head of Translation
Explore similar companies to NewLimit
Science
A brighter tomorrow enabled by neural engineering.
Biotech · Series C · Onsite · Based in Alameda
Loyal
Extending the lifespan of dogs.
Biotech · Series C · Remote · Based in San Francisco
Kingdom Supercultures
Natural functional ingredients that actually work.
Biotech · Series A · Onsite · Based in New York
CuspAI
Frontier AI for breakthrough materials.
Biotech · Series A · Remote · Based in London
Cortical Labs
Lab-grown neurons with silicon chips.
Biotech · Seed · Remote · Based in Melbourne
Convoke
AI-native OS for drug development.
Biotech · Seed · Onsite · Based in San Francisco
Converge Bio
Accelerating therapeutic breakthroughs with AI.
Biotech · Series A · Remote · Based in Tel Aviv
Mantis Biotech
Infrastructure for human-in-computer models.
Biotech · Seed · Onsite · Based in New York
Bindwell
Building better pesticides with AI.
Biotech · Seed · Onsite · Based in San Francisco
Industries
Investors
Cities